anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 222,451-222,480
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

222,451-222,480 of 303,780

filter-aware
06
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
The slide uses a 'Target vs Status' framework to demonstrate progress.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
08
The slide outlines specific milestones including FDA approval, manufacturing scale-up, US market entry, and D2C expansion.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
10
The slide highlights the UI/UX of the companion app for the sugarBEAT CGM device.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
11
The slide uses a pie chart graphic as a visual metaphor for market segmentation, though it does not contain actual data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
12
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
13
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
14
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
15
The superscript 3 in '2000^3' appears to be a typo or formatting error in the source slide.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
16
The slide contrasts a large incumbent's metrics with the company's own USP.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · Competition1 hit
17
The slide outlines CE marking in Europe and the ongoing FDA PMA review process, including specific audit and inspection history.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
20
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
21
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
22
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
01
Slide 1
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
02
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
03
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
04
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
05
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
06
The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
15
Includes qualitative expert testimonials regarding pricing and market access.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Market Sizing1 hit
16
The diagram illustrates a decision-tree process based on clinical trial outcomes.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
17
Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit